Skip to main content

Table 1 Patients’ characteristics

From: Bioactive glass BAG-S53P4 for the adjunctive treatment of chronic osteomyelitis of the long bones: an in vitroand prospective clinical study

Patient Age (years) Sex Site Previous surgeries Infection duration (months) Pathogenesis Stage Host type
1 35 F Tibia 3 12 Post-traumatic 4 A
2 50 M Femur 5 60 Post-traumatic 3 B (smoker)
3 60 M Femur 2 18 Haematogenous 1 B (lymphoma, chemotherapy)
4 47 M Tibia 4 54 Haematogenous 1 C (smoker, vasculopathy, diabetes)
5 35 M Femur 1 18 Post-traumatic 3 A
6 23 M Tibia 1 9 Post-surgical 3 A
7 80 M Tibia 3 38 Post-surgical 3 B (psoriasis, corticosteroids)
8 41 M Tibia 2 12 Post-surgical 3 A
9 38 M Femur 1 36 Post-surgical 3 A
10 28 M Femur 1 12 Post-surgical 3 A
11 40 F Femur 1 12 Post-traumatic 3 B (tumor, radiotherapy)
12 50 F Humerus 0 10 Haematogenous 1 B (rheumatoid arthritis)
13 40 F Tibia 3 24 Post-traumatic 2 B ( peripheral vasculopathy)
14 60 M Tibia 2 12 Post-traumatic 4 B (smoker)
15 44 M Tibia 3 24 Post-traumatic 3 B (smoker, alcol abuse)
16 36 F Tibia 0 6 Haematogenous 1 A
17 55 M Tibia 2 12 Post-surgical 3 B (smoker, peripheral vasculopathy)
18 20 M Tibia 0 6 Haematogenous 1 A
19 36 M Tibia 2 6 Post-surgical 3 A
20 40 M Femur 2 12 Post-surgical 3 B (smoker, peripheral vasculopathy)
21 30 M Tibia 0 10 Haematogenous 1 B (tetraplegia, recurrent pneumonia and urinary tract infection)
22 50 F Tibia 2 24 Post-traumatic 3 B (smoker)
23 52 F Tibia 2 12 Haematogenous 1 B (diabetes, peripheral neuropathy)
24 50 M Tibia 2 12 Post-surgical 3 B (Churg-Strauss disease, immunosuppression)
25 61 F Foot 2 12 Post-surgical 3 B (diabetes)
26 60 M Tibia 2 6 Post-traumatic 3 B (smoker)
27 20 F Tibia + Femur 0 12 Haematogenous 1 B (immunosuppressive therapy)